%0 Journal Article
%T Severe Esophagitis and Gastritis from Nivolumab Therapy
%A Justin Boike
%A Todd Dejulio
%J Archive of "ACG Case Reports Journal".
%D 2017
%R 10.14309/crj.2017.57
%X Nivolumab is a novel chemotherapy currently approved for the treatment of multiple metastatic malignancies. This class of therapy, known as immune checkpoint inhibitors, is notable for an autoimmune-related adverse event profile. Diarrhea and colitis are common gastrointestinal adverse events, however, upper gastrointestinal events are rarely reported. We present a case of nivolumab-associated esophagitis and gastritis that has yet to be reported in the published literature
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404341/